Aminoglutethimide (AG) has been the most widely used aromatase inhibitor in breast cancer patients to date. Commercially, AG (Orimeten) is available as a racemate (DL-AG). Previous studies suggested the stereoisomers of AG (D-AG and L-AG) to differ considerably in their affinities and potencies to inhibit different cytochrome P-450-dependent enzymes, with D-AG being the potent aromatase inhibitor. DL-AG, apart from being an aromatase inhibitor, is known to enhance the metabolism of plasma estrone sulfate (E 1 S). In the present study we compared the effects of D-AG (500 mg daily) and DL-AG (1000 mg daily) on plasma estrogen levels and estrone (E 1 ) and E 1 S clearance rates, determined after the injection of [ 14 C]E 1 and [ 3 H]E 1 S, in a cross-over study involving 12 postmenopausal breast cancer patients. Treatment with DL-AG and D-AG suppressed plasma E 1 S to 18.6% and 15.0% of pretreatment levels, whereas E 1 and estradiol E 2 levels fell to 18.6% and 23.4% of their pretreatment levels during treatment with DL-AG and to 17.7% and 23.4% during treatment with D-AG, respectively. Thus, both treatment options suppressed all estrogens measured to a similar extent. The clearance rate of E 1 S increased from a mean pretreatment value of 5.9 to 14.0 and 10.0 L/h during treatment with DL-AG and D-AG, respectively (P Ͻ 0.05, comparing the two on-treatment situations), whereas the production rate of E 1 S decreased from a pretreatment value of 1.44 to 0.64 nmol/h with DL-AG and 0.36 nmol/h with D-AG (P Ͻ 0.05, comparing on-treatment values). These findings are consistent with the hypothesis that the Das well as the L-form of AG may enhance the clearance rate of E 1 S. The finding of a higher estrogen production rate during treatment with DL-AG compared to D-AG probably reflects an increased plasma level of the estrogen precursor androstenedione (mean levels of androstenedione of 2.54 and 1.27 nmol/L during treatment with D-AG and DL-AG, respectively; P Ͻ 0.05). (J Clin Endocrinol Metab 83: [2687][2688][2689][2690][2691][2692][2693] 1998) A MINOGLUTETHIMIDE (AG) is the aromatase inhibitor most widely used for treatment of postmenopausal women with metastatic breast cancer. However, a major disadvantage of AG is its lack of specificity. In addition to being an aromatase inhibitor, AG inhibits several other P-450-dependent enzymes involved in adrenal steroid synthesis (1-5).
A MINOGLUTETHIMIDE (AG) is the aromatase inhibitor most widely used for treatment of postmenopausal women with metastatic breast cancer. However, a major disadvantage of AG is its lack of specificity. In addition to being an aromatase inhibitor, AG inhibits several other P-450-dependent enzymes involved in adrenal steroid synthesis (1) (2) (3) (4) (5) .
Commercial AG (Orimeten, Novartis, Basel, Switzerland) exists as a racemate (dl-AG; Fig. 1 ). Previous studies suggest considerable differences between the two enantiomers of AG in their affinities for different enzymes of the P-450 superfamily. In vitro observations showed dexaminoglutethimide (d-AG) to be 38-fold more potent in suppressing the aromatization of androstenedione to estrone (E 1 ) compared to l-AG (6), but to express about 2.5 times the inhibitory activity of the l-form with respect to the cholesterol side-chain cleavage enzyme (7) .
In addition to being an enzyme inhibitor, AG is known to induce cytochrome P-450-dependent mixed function oxidases (8) and to increase the plasma clearance rates of several xenobiotics (9) as well as estrone sulfate (E 1 S) (10) . Thus, this effect of AG may be beneficial because it may contribute to estrogen suppression and the antitumor effects of AG in breast cancer (11) .
Whether the enzyme induction and the influence on E 1 S metabolism are caused by a single or both enantiomers of AG is currently not known. As aromatase inhibition is caused by d-AG alone, a finding that the d-form may be responsible for the induction of E 1 S metabolism may encourage the development of d-AG as a therapeutic drug. To test this hypothesis, we evaluated the influence of d-AG vs. dl-AG on estrogen disposition in 12 postmenopausal women suffering from metastatic breast cancer in a blinded, cross-over design study. Plasma levels of E 1 , estradiol (E 2 ), and E 1 S were measured by highly sensitive RIAs, and the clearance rate of E 1 and E 1 S were determined after tracer injections of [ 3 H]E 1 S and [
14 C]E 1 before and after 4 weeks of treatment with each drug regimen.
Subjects and Methods Patients
The study was designed to enroll a sufficient number of patients to allow statistical comparisons in a group of at least 12 patients. Thirteen postmenopausal women considered for treatment with an aromatase inhibitor for stage IV breast cancer were eligible for this study. Tumor characteristics and demographic data of the patients are given in Table  1 . Due to intolerable side-effects (fever and skin rash), the investigators decided to withdraw 1 patient (no. 12) from the study after 2 weeks of treatment, leaving 12 patients for statistical analysis. The median age of all participants was 75 yr (range, 60 -81 yr), and the mean weight was 69.5 kg (range, 56 -78 kg). All patients gave their written informed consent before participation, and the study was approved by the regional ethical committee.
Treatment
The protocol was designed as a double blind, cross-over study. dl-AG and dexaminoglutethimide (d-AG) were supplied by Chiroscience Ltd. (Cambridge, UK). Patients were all randomized to receive either dl-AG (1000 mg daily) or d-AG (500 mg daily) for a period of 4 weeks each and were then crossed over to the alternative treatment regimen for another 4 weeks without any wash-out period. This design was justified by previous work establishing the half-life of AG to be about 7 h in postmenopausal women (12) . The treatment was dl-AG (250 mg, four times daily) or d-AG (125 mg, four times daily). On the days before radiotracer injections, the last drug dose was administered at 2200 h, and the first medication during the tracer experiments was given 2 h after the radiotracer injection. Cortisone acetate was administered as 50 mg, two times daily, for the first 2 weeks of treatment, followed by 25 mg, two times daily (13) . After the 8-week study period was completed, all patients continued treatment with AG racemate (250 mg, two times daily) and cortisone acetate (25 mg, four times daily) until disease progression occurred.
Sample collection
Fasting blood samples for plasma hormone measurements were obtained at 0800 h before initiation of treatment and on days 28 and 56 during treatment. All samples were collected in sodium-heparinized vials before drug intake and before tracer injections. Plasma was separated by centrifugation and was stored at Ϫ20 C until analysis.
Investigational protocol
The steroid injection technique, blood-sampling protocol, and measurement of labeled estrogens in plasma were previously described (10) . The pharmacokinetic calculations of the MCRs as well as the production rates of E 1 and E 1 S were performed as described elsewhere (11) .
Materials
All solvents were of analytical or spectrophotometrical grade and were obtained from Merck (Darmstadt, Germany), except for ethanol, which was obtained from A/S Vinmonopolet (Oslo, Norway). Radiolabeled [6, H]E 1 S (40 -60 Ci/mmol) for recovery calculation and for bolus injections was obtained from DuPont-New England Nuclear (Boston, MA). E 1 antiserum (E17-94) was purchased from Endocrine Sciences (Calabasas Hills, CA), the E 2 antibody (ER 150, Sorin Biomedica, Saluggia, Italy) was obtained from Sodiag (Losone, Switzerland), and the tracer [2,4,6,7- (57 Ci/mol) was obtained for the bolus injections from New England Nuclear Products (Boston, MA).
Estrogen measurements
Plasma estrogen levels were measured by methods reported previously (14 -16) . To measure plasma E 1 and E 1 S, [ 3 H]E 1 S (Х1000 cpm) dissolved in methanol was added to test tubes and evaporated to dryness. Two milliliters of plasma were added, and the samples were allowed to equilibrate overnight. Free (unconjugated) estrogens were extracted with ether (three times, 5 mL each time). The ether extracts were removed, evaporated to dryness, and reconstituted in dichlormethane-ethyl acetate-methanol (97:5:1, vol/vol/vol) before purification of the E 1 fraction on LH-20 columns (1.6 mL). The separated fractions for E 1 were then evaporated to dryness and reconstituted in methanol. Estrone was measured by RIA using the tracer [2,4,6,7- 3 H]estrone and the antibody E17-94. The results were corrected for the recovery of E 1 (85%) based on repeated analyses in our laboratory (15) .
After ether extraction, ethanol (12 mL) was added to the water fraction, and the sample was vortexed and centrifuged for 15 min at 600 ϫ g. The ethanol fraction was removed and dried, and the residue was reconstituted in 2 mL acetate buffer (0.2 mol/L; pH 5) containing sulfatase (S-9754) to a final concentration of 0.2 mg/mL. Hydrolysis was allowed for 48 h at 37 C, followed by extraction of free estrogens and purification of the E 1 fraction on an LH-20 column as outlined above. E 1 was subsequently converted to E 2 with use of sodium borohydride dissolved in 0.05 mol/L NaOH to a final concentration of 1 mg/mL in NaOH-methanol (1:10, vol/vol). After incubation at 37 C for 15 min, the methanol was evaporated, and borohydride was neutralized by adding 0.5 mL acetate buffer (0.2 mol/L; pH 3.0). E 2 was extracted by ether and purified on LH-20 columns as outlined above. The E 2 fraction was evaporated to dryness and reconstituted in 1 mL methanol. A 500-L aliquot was obtained for recovery calculation. From the residual 500 L, 150-L aliquots were obtained in duplicate, and the E 2 concentration was measured by RIA using estradiol-6-(O-carboxymethyl)oximino-2-(2-[ 125 I]iodohistamine) as the tracer and the antibody ER 150 (Sorin). For the measurement of E 2 , plasma (0.2 mL) was extracted with 3 mL ether, and E 2 concentrations were measured directly by RIA without recovery calculation as described previously (14, 15) .
The intraassay coefficient of variation was below 7% for all measurements, and the sensitivity limit for E 1 , E 2 , and E 1 S was 6.3, 2.1, and 2.7 pmol/L, respectively (15, 16) .
Measurement of plasma androgens
Plasma levels of androstenedione and testosterone were measured with commercial RIA kits provided by Diagnostic Systems Laboratories (Webster, TX) and Diagnostic Products Corp. (Los Angeles, CA).
Determination of AG in plasma samples
Plasma levels of AG were measured in fasting blood samples obtained on days 0, 14, 28, 42, and 56. Although the measurements for the second treatment started only 2 weeks after completing the first treatment, the half-life of AG (ϳ7 h) suggests that all of the drug administered during the first treatment had been completely cleared from the body by the time these measurements were made. Heparinized vials were collected, centrifuged, and the plasma was stored at Ϫ20 C until analysis. All samples from one patient were analyzed in the same batch. After a protein precipitation, liquid chromatography with mass spectrometric detection was used to determine plasma AG levels. The method has been validated over the range 0.25-10.0 g/mL. Samples above this concentration had to be diluted into this range. The analysis has been carried out at Covance Laboratories (Madison, WI).
Evaluation of side-effects
Side-effects such as sedation, dizziness, nausea, and skin rash were evaluated before commencing therapy and on each visit during treatment (after 2 and 4 weeks on each regimen) by the same clinician.
Statistics
In a previous study, we found plasma estrogen levels to be well fitted to a log-normal distribution (15) . Thus, plasma hormone levels as well as clearance and production rates are given as their geometric mean value with 95% confidence intervals of the mean. In addition, values obtained in the three test situations were compared using the Friedman test. If this revealed a significant difference between the test situations, values obtained during treatment with dl-AG and d-AG were compared using the Wilcoxon matched pair signed rank test. All P values are expressed as two-tailed. In cases with hormone levels suppressed below the sensitivity limits of the assays, the value of the sensitivity limit was used for statistical analysis.
Results
Plasma estrogen levels obtained before initiation of treatment and during treatment with dl-AG and d-AG are given in Table 2 and Fig. 2 . In addition, plasma levels of E 1 , E 1 S, and androstenedione as well as E 1 and E 1 S plasma clearance and production rates measured before and during the two treatment options are shown in Fig. 3 .
Plasma estrogen suppression
Plasma levels of E 1 were found suppressed from a pretreatment value of 41.7 pmol/L [95% confidence interval (CI), 29.6 -58.8) to 7.7 pmol/L (95% CI, 6.1-9.8) and 7.4 pmol/L (95% CI, 6.3-8.6) during treatment with dl-AG and d-AG, corresponding to suppression to 18.6% and 17.7% of pretreatment levels, respectively. Noteworthy, plasma E 1 levels were suppressed below the sensitivity limit of the assay in seven patients during treatment with dl-AG and in four patients during d-AG therapy. E 2 was equally suppressed by both treatment regimens from a pretreatment value of 15.4 pmol/L (95% CI, 11.4 -20.9) to 3.6 pmol/L (95% CI, 3.0 -4.3 for both regimens) during treatment (mean sup- 
Plasma clearance and production rates of E 1 and E 1 S
Treatment with dl-AG increased the clearance rate of E 1 S from a mean of 5.9 L/h (95% CI, 3.9 -9.0) before treatment to 14.0 L/h (95% CI, 10.0 -19.7), whereas d-AG increased the clearance rate of E 1 S to 10.0 L/h (95% CI, 7.3-13.7; P ϭ 0.001; mean increase, 136.3% and 68.7%, P ϭ 0.001, respectively). The production rate of E 1 S decreased from a pretreatment value of 1.44 nmol/h (95% CI, 0.94 -2.21) to 0.64 nmol/h (95% CI, 0.41-1.02) and 0.36 nmol/h (95% CI, 0.23-0.57) during treatment with dl-AG and d-AG, respectively (P Ͻ 0.005; 44.7% and 25.2% of pretreatment levels). The observed differences between the E 1 S clearance rates and the E 1 S production rates during treatment with dl-AG and d-AG both reached a level of statistical significance (P Ͻ 0.05).
The plasma clearance rate of E 1 increased from a pretreatment value of 44.8 L/h (95% CI, 37.3-53.8) to 58.5 L/h (95% CI, 50.0 -68.4) and 50.6 L/h (95% CI, 42.5-60.1) during treatment with dl-AG and d-AG, respectively (P Ͻ 0.05; mean increase of 30.5% and 12.9%, respectively). The production rate of E 1 decreased from a pretreatment value of 1.87 nmol/h (95% CI, 1.18 -2.95) to 0.45 nmol/h (95% CI, 0.32-0.64) during dl-AG treatment and to 0.37 nmol/h (95% CI, 0.29 -0.49) during d-AG treatment (P ϭ 0.001; 24.3% and 20.0% of pretreatment values, respectively). The observed changes in the clearance and production rate of E 1 (for details see Table 2 ) paralleled in general the findings made for E 1 S, but the difference between values obtained during treatment with d-AG and dl-AG did not reach a level of statistical significance (P Ͼ 0.10 for both).
Plasma androgen levels
Plasma levels of androstenedione and testosterone determined before and during treatment are given in Table 2 . Treatment with d-AG suppressed plasma androstenedione levels significantly (to a mean of 1.3 nmol/L), whereas androstenedione levels during treatment with dl-AG (mean, 2.5 nmol/L) were unchanged compared with pretreatment values (mean, 2.2 nmol/L; P Ͻ 0.05 comparing the three test situations and P Ͻ 0.05 comparing the two on-treatment situations). No changes in plasma testosterone values were observed during either treatment.
Plasma levels of AG
Morning plasma levels of AG were 6.50 g/mL for the total racemate (95% CI, 5.16 -8.20) and 2.11 g/mL (95% CI, 1.67-2.68) during treatment with dexaminoglutethimide, respectively (P Ͻ 0.005).
Side-effects
Side-effects observed during treatment with dl-AG and d-AG are reported in Table 3 . In general, side-effects appeared during the first 2 weeks of treatment with the first drug schedule, with no significant difference in the frequency of side-effects between d-AG and dl-AG treatments.
Discussion
Pretreatment values for E 1 and E 2 were in the lower normal range for postmenopausal women previously reported from our laboratory (15) . It is noteworthy that most of our patients were heavily pretreated. Three of the participating women also had very low pretreatment levels of E 1 S (Ͻ100 pmol/L), reflecting the variance of this parameter in a group of heavily pretreated breast cancer patients.
AG is well recognized for being a nonspecific drug causing many biochemical effects. It is known as an unselective inhibitor of several P-450-dependent enzymes involved in steroid formation, such as desmolase as well as 11␤-, 18-, and (probably) 21-hydroxylase, requiring glucocorticoid administration in concert (17) . The drug causes several side-effects on the central nervous system, i.e. dizziness, sedation, and nausea, as well as skin rash and fever. Whether these effects are caused by one or both of the enantiomers is not known. AG is also a potent enhancer of P-450 mixed function hydroxylases (8) , and in previous studies we demonstrated dl-AG to cause an increase in the plasma clearance rate of E 1 S by more than 100%, probably by induction of 16␣-hydroxylation (10, 18) , one of the main metabolic pathways of estrogens in man (19) .
In the present trial, treatment with dl-AG (1000 mg) and d-AG (500 mg) suppressed plasma levels of E 1 by at least 80%, whereas plasma E 2 levels decreased by 76.6% during both treatment options. This suppression is somewhat better than what has been reported in previous studies (20, 21) . Although highly sensitive RIAs were used, we found plasma levels of E 1 in several patients to be suppressed below the detection limit of the assay during both treatment options.
Thus, the suppression of plasma E 1 levels may be underestimated. Plasma levels of E 1 S decreased during treatment with both regimens by 80 -85%. Notably, patients with low pretreatment values of E 1 S showed a smaller percent suppression than patients with higher pretreatment E 1 S levels. No significant difference between plasma levels of any of the estrogens during treatment with d-AG and dl-AG was seen.
The plasma clearance rate of E 1 S increased 2-fold during treatment with d-AG and 3-fold during treatment with dl-AG compared to pretreatment values. Meanwhile, the production rate of E 1 S decreased more extensively during treatment with the d-enantiomer compared with dl-AG. The reason for this discrepancy is probably the drop in plasma androstenedione levels during treatment with d-AG. Changes in plasma androgen levels during treatment with AG have been discussed in detail previously (17, 22) . When administered without glucocorticoids, AG causes a profound rise in plasma 17-hydroxyprogesterone and androstenedione, probably due to 11␤-and 21-hydroxylase inhibition followed by substrate accumulation (17) . When AG is administered with glucocorticoid substitution, a significant suppression of ⌬ 5 -steroids occurs, whereas ⌬ 4 -steroids, in general, remain unchanged (17) . In the present trial, both treatment options were administered with similar doses of a glucocorticoid. The finding that treatment with d-AG suppressed plasma levels of androstenedione, contrary to treatment with dl-AG, may be due to a more profound inhibition of the adrenal 11␤-hydroxylase (and probably 21-hydroxylase) with use of the racemic compound, suggesting that a lower glucocorticoid dose may be required to balance this effect during treatment with the d-AG regimen. This drop in plasma androstenedione levels may explain a lower production rate of E 1 and E 1 S during treatment with d-AG, supporting the hypothesis of Dowsett and Harris (23) that changes in plasma androstenedione levels may influence plasma estrogen levels in patients receiving treatment with aromatase inhibitors. Thus, a more profound reduction in estrogen production rates during treatment with d-AG may counteract a more profound enhancement of the E 1 S clearance rate during treatment with dl-AG, resulting in similar 
Side-effects were scored as: Ϫ, absent; 1, minimal; 2, moderate; 3, severe; and 4, intolerable using common toxicity criteria. All side-effects are given after 2 (x/) and 4 (/x) weeks on treatment with the individual drug formulation.
a Switched from DL-AG to D-AG. b Switched from D-AG to DL-AG.
plasma estrogen levels during treatment with the two regimens. Previous publications showed AG to be a phenobarbitallike inducer of cytochrome P-450-dependent enzymes (8, 9) . Although several studies have suggested a difference between the enantiomers of AG concerning enzyme-inhibiting properties (6, 24, 25) , little is known about chiral effects on enzyme induction in man. In vitro and animal investigations on barbiturates have provided conflicting evidence about whether one or both enantiomers are responsible for the induction of P-450-dependent enzymes, as some studies have suggested stereoselective enhancement of P-450-dependent mixed function oxidases with the d-isomer being the biological active part (26) , whereas others have reported both stereoisomers to be active in this respect (27) . The finding in this study that both regimens enhanced E 1 S metabolism but this effect was more profound with the dl-AG racemate suggests both enantiomers of AG to be involved in the enhancement of plasma E 1 S clearance. Noteworthy, previous results have shown AG to enhance warfarin metabolism in a dose-dependent manner when administered in the 250-1000 mg/day dose range (9) , suggesting that a drug dose of 500 mg may be inferior to 1000 mg daily with respect to enzyme induction. Whether l-AG is active as an enzyme inducer on its own or acts indirectly via interaction with the metabolism of the d-enantiomer, as has been shown for other drugs (28) , is currently unknown. Although the finding that AG levels during treatment with dl-AG were 3-fold and not 2-fold higher than plasma levels obtained during treatment with d-AG could be consistent with such a hypothesis, this observation should be interpreted carefully. First, plasma levels were measured in single samples obtained in the morning and thus may not be fully representative of mean 24-h plasma samples. Noteworthy, the half-life of the AG enantiomers has not been measured separately. Secondly, AG is known to induce its own metabolism (29) , but whether this is effected by enhancing the metabolism of both enantiomers is not known.
AG is known to cause several side-effects, the most important being neurological, such as sedation, and skin rash. These side-effects occur mainly during the first 2 weeks after initiation of treatment (17) . Although animal experiments have suggested both enantiomers to be responsible for the neurological side-effects (30) , with the exception of one previous small study (31) , this hypothesis has not been evaluated in humans to date. In theory, by using the single disomer in a lower dosage (500 mg daily) compared to the standard dosage of the racemate (1000 mg daily) this may reduce neurological side-effects even if they are caused by both enantiomers. However, we found treatment with d-AG (500 mg daily) to cause side-effects at the same frequency and intensity as treatment with dl-AG (1000 mg daily). These findings contrast with the observations made by others (31) that even higher doses of d-AG (900 mg daily) are well tolerated.
Our results show both treatment options to be equally effective in suppressing plasma estrogen levels and to cause the same profile of side-effects. Although l-AG is known to be ineffective as an aromatase inhibitor, our findings do not suggest any major clinical advantage from eliminating this enantiomer from the drug.
In conclusion, our finding of a higher E 1 S clearance during treatment with dl-AG compared to d-AG alone suggests both the d-and l-forms of AG to influence E 1 S metabolism. Considering E 1 S is an important estrogen source for the tumor cell, obviously a reduction in the plasma level of this hormone by enhancing its metabolism is an interesting approach to achieve maximal estrogen suppression. This observation together with the finding that suppression of plasma androstenedione influences estrogen levels in patients during treatment with a potent aromatase inhibitor suggest that future strategies with combined drug treatment regimens attaching E 1 S metabolism or suppressing androstenedione levels in addition to aromatase inhibition could be beneficial to achieve maximal estrogen suppression in breast cancer patients.
